CN104428002B - 热成形的抗篡改含锌药物剂型 - Google Patents

热成形的抗篡改含锌药物剂型 Download PDF

Info

Publication number
CN104428002B
CN104428002B CN201380024652.2A CN201380024652A CN104428002B CN 104428002 B CN104428002 B CN 104428002B CN 201380024652 A CN201380024652 A CN 201380024652A CN 104428002 B CN104428002 B CN 104428002B
Authority
CN
China
Prior art keywords
pharmaceutical dosage
dosage form
weight
polyalkylene oxide
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380024652.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN104428002A (zh
Inventor
L.巴恩沙伊德
E.加利亚
A.盖斯勒
J.珀茨
S.施维尔
J.巴龙斯基-普罗布斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of CN104428002A publication Critical patent/CN104428002A/zh
Application granted granted Critical
Publication of CN104428002B publication Critical patent/CN104428002B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201380024652.2A 2012-05-11 2013-05-10 热成形的抗篡改含锌药物剂型 Expired - Fee Related CN104428002B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12003743.7 2012-05-11
EP12003743 2012-05-11
PCT/EP2013/059728 WO2013167735A1 (en) 2012-05-11 2013-05-10 Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc

Publications (2)

Publication Number Publication Date
CN104428002A CN104428002A (zh) 2015-03-18
CN104428002B true CN104428002B (zh) 2017-08-11

Family

ID=48407572

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380024652.2A Expired - Fee Related CN104428002B (zh) 2012-05-11 2013-05-10 热成形的抗篡改含锌药物剂型

Country Status (21)

Country Link
EP (1) EP2846835B1 (https=)
JP (2) JP2015516406A (https=)
CN (1) CN104428002B (https=)
AU (1) AU2013257943B2 (https=)
BR (1) BR112014026768A2 (https=)
CA (1) CA2870012A1 (https=)
CY (1) CY1119637T1 (https=)
DK (1) DK2846835T3 (https=)
EA (1) EA029171B1 (https=)
ES (1) ES2650945T3 (https=)
HR (1) HRP20171718T1 (https=)
HU (1) HUE035123T2 (https=)
IL (1) IL234815A0 (https=)
LT (1) LT2846835T (https=)
MX (1) MX357783B (https=)
NO (1) NO2846835T3 (https=)
PL (1) PL2846835T3 (https=)
PT (1) PT2846835T (https=)
RS (1) RS56685B1 (https=)
SI (1) SI2846835T1 (https=)
WO (1) WO2013167735A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
TWI473628B (zh) 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型
WO2011009602A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Hot-melt extruded controlled release dosage form
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
ES2648129T3 (es) 2011-07-29 2017-12-28 Grünenthal GmbH Pastilla a prueba de manipulación que proporciona una liberación inmediata de un medicamento
AU2012289764B2 (en) 2011-07-29 2017-03-02 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
MX2017013643A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
US20160310437A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
CA2983640A1 (en) 2015-04-24 2016-10-27 Grunenthal Gmbh Tamper-resistant fixed dose combination providing fast release of two drugs from different particles
US10183018B2 (en) 2015-05-28 2019-01-22 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
US11234974B2 (en) 2015-05-28 2022-02-01 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101027044A (zh) * 2004-07-01 2007-08-29 格吕伦塔尔有限公司 避免滥用的口服剂型
CN101198317A (zh) * 2005-06-13 2008-06-11 弗拉梅技术公司 含抗滥用系统的口服剂型
EP2402004A2 (en) * 2003-11-26 2012-01-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
EP0239973A3 (en) 1986-03-31 1989-11-08 Union Carbide Corporation Catalyst and process for alkylene oxide polymerization
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
US4667013A (en) 1986-05-02 1987-05-19 Union Carbide Corporation Process for alkylene oxide polymerization
JP3073054B2 (ja) * 1991-07-11 2000-08-07 住友精化株式会社 アルキレンオキシド重合体の製造方法
JP2002265592A (ja) 2001-03-07 2002-09-18 Sumitomo Seika Chem Co Ltd アルキレンオキシド重合体の製造方法
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
ATE381924T1 (de) 2001-09-21 2008-01-15 Egalet As Feste dispersionen mit kontrollierter freisetzung von carvedilol
US7300668B2 (en) 2001-10-29 2007-11-27 Massachusetts Institute Of Technology System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
NZ545202A (en) 2003-08-06 2010-03-26 Gruenenthal Chemie Abuse-proofed dosage form comprising opiods and a high molecular weight polyethylene oxide
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
PL1740156T3 (pl) 2004-04-22 2011-12-30 Gruenenthal Gmbh Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej
WO2005105036A1 (en) * 2004-04-28 2005-11-10 Natco Pharma Limited Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
CA2572491A1 (en) 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse
BRPI0513300B1 (pt) 2004-07-01 2018-11-06 Gruenenthal Gmbh forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
EP1765298B1 (de) 2004-07-01 2012-10-24 Gruenenthal Gmbh Verfahren zur herstellung einer gegen missbrauch gesicherten, festen darreichungsform unter verwendung eines planetwalzenextruders
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP2104493A2 (en) 2007-01-16 2009-09-30 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
KR101616246B1 (ko) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 약제학적 투여형
EP2376065A2 (en) 2008-11-14 2011-10-19 Portola Pharmaceuticals, Inc. Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low ph and methods of use thereof
TWI473628B (zh) * 2009-07-22 2015-02-21 用於對氧化敏感之類鴉片藥劑之抗破壞劑型

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402004A2 (en) * 2003-11-26 2012-01-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
CN101027044A (zh) * 2004-07-01 2007-08-29 格吕伦塔尔有限公司 避免滥用的口服剂型
CN101198317A (zh) * 2005-06-13 2008-06-11 弗拉梅技术公司 含抗滥用系统的口服剂型

Also Published As

Publication number Publication date
HUE035123T2 (en) 2018-05-02
CA2870012A1 (en) 2013-11-14
AU2013257943B2 (en) 2017-10-05
EA201401240A1 (ru) 2015-04-30
DK2846835T3 (en) 2017-12-04
CY1119637T1 (el) 2018-04-04
SI2846835T1 (en) 2018-01-31
RS56685B1 (sr) 2018-03-30
EP2846835A1 (en) 2015-03-18
IL234815A0 (en) 2014-12-31
HK1207978A1 (en) 2016-02-19
EA029171B1 (ru) 2018-02-28
ES2650945T3 (es) 2018-01-23
WO2013167735A1 (en) 2013-11-14
HRP20171718T1 (hr) 2017-12-29
PL2846835T3 (pl) 2018-02-28
BR112014026768A2 (pt) 2017-06-27
NO2846835T3 (https=) 2018-02-03
JP2018065810A (ja) 2018-04-26
EP2846835B1 (en) 2017-09-06
MX2014013095A (es) 2014-12-08
JP6541748B2 (ja) 2019-07-10
MX357783B (es) 2018-07-25
PT2846835T (pt) 2017-12-15
LT2846835T (lt) 2017-12-27
JP2015516406A (ja) 2015-06-11
CN104428002A (zh) 2015-03-18
AU2013257943A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
CN104428002B (zh) 热成形的抗篡改含锌药物剂型
US10064945B2 (en) Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10300141B2 (en) Tamper resistant dosage form comprising inorganic salt
EP2611428B1 (en) Tamper resistant dosage form comprising an anionic polymer
CN105682643B (zh) 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
KR20130137627A (ko) 음이온성 중합체를 포함하는 내변조성 투여형
HK1207978B (en) Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
HK1184384B (en) Tamper resistant dosage form comprising inorganic salt
HK1184384A (en) Tamper resistant dosage form comprising inorganic salt
HK1184389B (en) Tamper resistant dosage form comprising an anionic polymer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170811

Termination date: 20200510

CF01 Termination of patent right due to non-payment of annual fee